Tesaro Shows Good Potential With Major Approvals This Year
- Tesaro awaits the FDA decision for Rolapitant IV.
- Rolapitant oral was approved by the European Commission earlier this year.
- Tesaro is working on marketing its newly approved Zejula treatment, the first of its kind for ovarian cancer.
By S.Mitra, MBA (ISB)
Tesaro Inc. (NASDAQ:TSRO) has shown strong operating performance this year so far with significant drug approvals from the FDA and the European Commission. The company became the first FDA approved PARP inhibitor provider with Zejula while its Rolapitant oral was approved by the EC earlier this year. However, the operating performance did not translate to corresponding stock market results as the stock is currently trading over 30 percent lower than its 52 weeks high of $192.94, making it an interesting investment opportunity for short as well as long term investors.
The full post is available to investor members only. Subscribe here.